Attorney Reference Number 5585-70293-01

\$\(\frac{1}{2}\)

JUL 3 1 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re application of: Boden et al.

Application No. 10/521,628

Filed: September 8, 2005 Confirmation No. 2023

Commination 110. 2023

For: BETA SHEET TAPES RIBBONS IN

TISSUE ENGINEERING

Examiner: Not yet assigned

Art Unit: 1712

Attorney Reference No. 5585-70293-01

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)___

Date Mailed July 26, 2006

TRANSMITTAL LETTER

Enclosed is an Amendment and Response for the above application. The fee has been calculated as shown below.

| CLAIMS AS AMENDED | | | | | | | |
|--|---------------------|-------------------------|---|------------------|----------|--------|--|
| For | No. after amendment | No. paid for previously | | Present Extra | Rate | Fee | |
| Total Claims | 51 | - 51* | = | 0 | \$50.00 | \$0.00 | |
| Índep. Claims | 1 | - 3** | = | 0 | \$200.00 | \$0.00 | |
| Mult. Dep. Claims Fee (if not previously paid) | | | | | \$360.00 | \$0.00 | |
| TOTAL ADDITIONAL FEE FOR THIS AMENDMENT | | | | | \$0.00 | | |

^{*} greater of twenty or number for which fee has been paid.

Enclosed is a sequence listing:

pages paper copy; diskette; Statement in Compliance; and a copy of a Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures dated 07/13/2006.

No additional fee is required.

^{**} greater of three or number for which fee has been paid.

- Please charge any additional fees that may be required in connection with filing this amendment and any extension of time, or credit any overpayment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- If the Patent and Trademark Office determines that this amendment results in an additional application size fee for pages in excess of 100, please charge the fee to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 595-5301

cc: Docketing

 $\mathbf{B}\mathbf{y}$

Sheree Lynn Rybak, Ph. Registration No. 47,913

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS EO Box 1450

Vinguia 22313-1450

| U.S. APPLICATION NUMBER NO. | FIRST NAMED APPLICANT | ATTY. DOCKET NO |
|-----------------------------|-----------------------|-----------------|
| 10/521,628 | Neville Boden | 5585-70293-01 |

INTERNATIONAL APPLICATION NO.

PCT/GB03/03016 9/13/06 24197 I.A. FILING DATE KLARQUIST SPARKMAN PERMETED FOR: 07/15/2003 121 SW SALMON STREET

PRIORITY DATE 07/15/2002

SUITE 1600

PORTLAND, OR 97204 COMPUTER BOOK

CONFIRMATION NO. 2023 371 FORMALITIES LETTER

SCAN

OC000000019584306

Date Mailed: 07/13/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825 (d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821 (e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

DONNA S GREENE

Telephone: (703) 308-9140 EXT 222

PART 1 - ATTORNEY/APPLICANT COPY

| U.S. APPLICATION NUMBER NO. | INTERNATIONAL APPLICATION NO. | ATTY, DOCKET NO. |
|-----------------------------|-------------------------------|------------------|
| 10/521,628 | PCT/GB03/03016 | 5585-7029301 |

FORM PCT/DO/EO/922 (371 Formalities Notice)